Anti Venom Market, By Anti-venom Type (Polyvalent and Monovalent), By Product Type (Snake Antivenom, Scorpion Anti-venom, Spider Anti-venom, Others), By End User (Hospitals & clinics, Ambulatory Surgical Centers, Research Institutes, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Feb 2025

Code : CMI1249

Pages :175

Formats :

Excel and PDF

Industry : Biotechnology

Anti Venom Market Size and Trends

Global anti venom market is estimated to be valued at USD 1,382.0 Mn in 2025 and is expected to reach USD 2,495.7 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of 8.8% from 2025 to 2032.

Anti Venom Market Key Factors

To learn more about this report, Request sample copy

Rapid growth in biopharmaceutical industry and increasing cases of snake bites across various regions can boost demand for anti venoms. Rising investment by key players for development of monoclonal antibodies and recombinant anti venoms to reduce side effects can also drive the market growth. Growing availability of anti venoms, owing to capacity expansion by major companies along with ongoing clinical trials for advanced anti venom therapeutics can offer growth opportunities in the near future. However, short shelf life of anti-venoms and lack of awareness regarding snake bites in certain regions can hamper the market growth.

Rising Incidence of Snake Bites

With increasing human encroachment into natural habitats, there has been increase in interaction between snakes and humans. Several regions across the globe that are home to various species of venomous snakes have witnessed increase in reported cases of snake bites. Tropical and sub-tropical regions in Asia, Africa and Latin America have a high risk of snake bites due to the presence of various venomous species. Unfortunately, many of these regions have poor access to basic healthcare facilities and anti-venom treatments. According to some studies, it is estimated that around 5 million people suffer from snake bites annually around the world, out of which, around 1.8 to 2.7 million develop clinical manifestations of envenoming while 81,000 to 138,000 die due to snake bite. The true burden of snake bites is probably higher than reported owing to under-reporting from remote rural areas in developing nations. Some of the countries with highest incidence of snake bites include India, Sudan, Sri Lanka, Burma, Thailand and parts of Latin America. With growing population in these at-risk regions and continuous habitat destruction pushing snakes and humans into closer contact, there will be high number of snake encounters and resultant in the near future. This will boost demand for anti-venom treatments and immunoglobulins to treat clinical envenoming and prevent loss of lives.